Some preliminary data concerning the anodic behavior of the antineplastic agent methotrexate [59-05-2] are reported, and a HPLC method with electrochem. detection for its detn. in human serum and urine is described. The method uses a reversed-phase C15 column and isocratic elution with amperometric detection on glassy carbon at +0.95 V vs. Ag/AgCl ref. electrode. Sample treatment consists of a simple deproteinization step (serum) or an extn. procedure on Sep-Pak C15 cartridges (serum) or Amberlite column (urine). The detection limit for methotrexate in serum is 2.2 nmol/L. The method should prove useful for the evaluation of the drug pharmacokinetics in patients undergoing anticancer therapy
DETERMINATION OF THE ANTINEOPLASTIC AGENT METHOTREXATE IN BODY-FLUIDS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
PALMISANO, Francesco;CATALDI, Tommaso;
1985-01-01
Abstract
Some preliminary data concerning the anodic behavior of the antineplastic agent methotrexate [59-05-2] are reported, and a HPLC method with electrochem. detection for its detn. in human serum and urine is described. The method uses a reversed-phase C15 column and isocratic elution with amperometric detection on glassy carbon at +0.95 V vs. Ag/AgCl ref. electrode. Sample treatment consists of a simple deproteinization step (serum) or an extn. procedure on Sep-Pak C15 cartridges (serum) or Amberlite column (urine). The detection limit for methotrexate in serum is 2.2 nmol/L. The method should prove useful for the evaluation of the drug pharmacokinetics in patients undergoing anticancer therapyI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
